CymaBay Reports Second Quarter 2019 Financial Results and Provides Corporate Update

NEWARK, Calif., Aug. 07, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced financial results and a corporate update for the quarter ended June 30, 2019.